Palbocent 125 mg (Palbociclib) is an innovative oral medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib, the active ingredient in Palbocent, is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, enzymes that play a crucial role in the growth and division of cancer cells. By blocking…
Palboxen 125mg, containing the active ingredient Palbociclib, is a groundbreaking medication specifically designed for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. As a cyclin-dependent kinase (CDK) 4/6 inhibitor, Palboxen 125mg is vital in slowing down the growth and spread of cancer cells, offering hope to patients whose cancer has progressed after previous treatments. When used…
